Chrysamine G *CAS 6472-91-9*
Ordering information
Price | |
Catalog Number | |
Unit Size | |
Quantity |
Additional ordering information
Telephone | 1-800-990-8053 |
Fax | 1-800-609-2943 |
sales@aatbio.com | |
International | See distributors |
Bulk request | Inquire |
Custom size | Inquire |
Shipping | Standard overnight for United States, inquire for international |
Physical properties
Molecular weight | 482.44 |
Solvent | DMSO |
Storage, safety and handling
H-phrase | H303, H313, H333 |
Hazard symbol | XN |
Intended use | Research Use Only (RUO) |
R-phrase | R20, R21, R22 |
Storage | Freeze (< -15 °C); Minimize light exposure |
UNSPSC | 12352200 |
Overview | SDSProtocol |
See also: Neurodegeneration & Amyloid Staining
CAS 6472-91-9 | Molecular weight 482.44 |
Chrysamine G is a lipophilic, bis-salicylic acid analog of Congo Red that displays both high (Kd = 200 nM; Bmax = 1.13 moles per mole of Ab40) and low (Kd = 38.77 µM; Bmax = 23.10 moles per mole of Ab40) affinity binding sites for beta-amyloid (Ab) fibrils. It can cross the blood-brain barrier and serve as a useful probe for detecting senile plaques (Ab aggregate).
Calculators
Common stock solution preparation
Table 1. Volume of DMSO needed to reconstitute specific mass of Chrysamine G *CAS 6472-91-9* to given concentration. Note that volume is only for preparing stock solution. Refer to sample experimental protocol for appropriate experimental/physiological buffers.
0.1 mg | 0.5 mg | 1 mg | 5 mg | 10 mg | |
1 mM | 207.28 µL | 1.036 mL | 2.073 mL | 10.364 mL | 20.728 mL |
5 mM | 41.456 µL | 207.28 µL | 414.559 µL | 2.073 mL | 4.146 mL |
10 mM | 20.728 µL | 103.64 µL | 207.28 µL | 1.036 mL | 2.073 mL |
Molarity calculator
Enter any two values (mass, volume, concentration) to calculate the third.
Mass (Calculate) | Molecular weight | Volume (Calculate) | Concentration (Calculate) | Moles | ||||
/ | = | x | = |
References
View all 13 references: Citation Explorer
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo
Authors: Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM.
Journal: J Biol Chem (2005): 5892
Authors: Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM.
Journal: J Biol Chem (2005): 5892
Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain
Authors: Mathis CA, Wang Y, Klunk WE.
Journal: Curr Pharm Des (2004): 1469
Authors: Mathis CA, Wang Y, Klunk WE.
Journal: Curr Pharm Des (2004): 1469
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative
Authors: Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT.
Journal: J Neuropathol Exp Neurol (2002): 797
Authors: Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT.
Journal: J Neuropathol Exp Neurol (2002): 797
Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice
Authors: Ishii K, Klunk WE, Arawaka S, Debnath ML, Furiya Y, Sahara N, Shoji S, Tamaoka A, Pettegrew JW, Mori H.
Journal: Neurosci Lett (2002): 5
Authors: Ishii K, Klunk WE, Arawaka S, Debnath ML, Furiya Y, Sahara N, Shoji S, Tamaoka A, Pettegrew JW, Mori H.
Journal: Neurosci Lett (2002): 5
Amyloid binding ligands as Alzheimer's disease therapies
Authors: Lee VM., undefined
Journal: Neurobiol Aging (2002): 1039
Authors: Lee VM., undefined
Journal: Neurobiol Aging (2002): 1039
In vitro affinity of 99Tcm-labelled N2S2 conjugates of chrysamine G for amyloid deposits of systemic amyloidosis
Authors: Dezutter NA, Sciot RM, de Groot TJ, Bormans GM, Verbruggen AM.
Journal: Nucl Med Commun (2001): 553
Authors: Dezutter NA, Sciot RM, de Groot TJ, Bormans GM, Verbruggen AM.
Journal: Nucl Med Commun (2001): 553
Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis
Authors: Dezutter NA, L and man WJ, Jager PL, de Groot TJ, Dupont PJ, Tooten PC, Zekarias B, Gruys E, Verbruggen AM.
Journal: Amyloid (2001): 202
Authors: Dezutter NA, L and man WJ, Jager PL, de Groot TJ, Dupont PJ, Tooten PC, Zekarias B, Gruys E, Verbruggen AM.
Journal: Amyloid (2001): 202
In search of the ideal radiotracer for soft-tissue amyloid scanning
Authors: Lee VW, Shah NP.
Journal: Amyloid (2001): 220
Authors: Lee VW, Shah NP.
Journal: Amyloid (2001): 220
Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles
Authors: Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP.
Journal: Neurobiol Dis (2001): 1017
Authors: Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP.
Journal: Neurobiol Dis (2001): 1017
Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy
Authors: Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE.
Journal: Proc Natl Acad Sci U S A (2000): 6739
Authors: Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE.
Journal: Proc Natl Acad Sci U S A (2000): 6739